A November deal pegged Eli Lilly and Novo Nordisk GLP 1 obesity and diabetes drugs — Ozempic, Wegovy, Mounjaro, and Zepbound — at $245 a month in Medicare and Medicaid.
The Trump administration announced in November that it had struck a deal with Eli Lilly and Novo Nordisk to peg their blockbuster GLP-1 drugs, the obesity and diabetes medications sold as Ozempic, Wegovy, Mounjaro, and Zepbound, at $245 per month for patients in Medicare and Medicaid. For the first time, that price extended to obesity, a use Medicare had never covered. The deal was framed as a classic bargain: lower prices in exchange for higher volume.
The price only holds if private Medicare insurers agree to cover the drugs at a $50 copay.
That contingency was not disclosed when the deal was announced. According to STAT, both companies recently confirmed the private-insurance condition to the outlet, months after the White House took its victory lap. The deal, in other words, hinged on a swing variable the public, and most beneficiaries, could not see. Until Medicare Advantage plans sign on, the lower price is a promise, not a deliverable.
Here is how the mechanism works. Medicare itself, the federal program for people 65 and older, does not list drugs the way the deal describes. Coverage decisions for roughly half of Medicare beneficiaries are made by private Medicare Advantage plans, each with its own formulary and cost-sharing rules. The $245 figure sets a ceiling on what the federal programs pay, but reaching a beneficiary's medicine cabinet depends on whether a private plan voluntarily lists the drug, covers it across all indications, and charges the $50 copay spelled out in the deal's terms. None of that was spelled out in November.
The companies, for their part, already have what they wanted from day one: volume. With the administration's backing, the federal programs now cover a much larger patient pool than before, including the obesity use case Medicare had historically excluded. The list-price ceiling exists. Whether most patients actually pay the announced $245 is now a question for the private Medicare Advantage market, which answers one formulary decision at a time.
That is where the loophole lives. The public headline delivered a tidy number and a story about pharmaceutical restraint. The fine print pushed the price-discipline burden onto a layer of the system that beneficiaries cannot negotiate with and that the administration did not name when it announced the deal. If Medicare Advantage plans decline to cover GLP-1s broadly, or set higher copays, the "lower prices for higher volume" bargain collapses into "higher volume at unchanged prices," and the announced $245 figure becomes the cap, not the reality, for most patients.
Three signals are worth watching in the coming months. How many Medicare Advantage plans publicly commit to the $245 and $50 structure when they publish next year's formularies. Whether future administration drug-price announcements disclose contingent private-payer terms up front. And what beneficiary out-of-pocket costs actually look like once plans translate the deal into coverage rules. A deal announced as a price cap only becomes a price cap when the private layer agrees.